S Matthaei1, N Aggarwal2, P Garcia-Hernandez3, N Iqbal4, H Chen5, E Johnsson6, A Chin5, L Hansen7. 1. Diabetes-Zentrum, Quakenbrück Hospital, Quakenbrück, Germany. 2. Aggarwal and Associates, Ltd, Brampton, Ontario, Canada. 3. Servicio de Endocrinologia, Hospital Universitario Dr. José Eleuterio Gonzalez, Monterrey, Nuevo Leon, Mexico. 4. Global Medicines Development, AstraZeneca, Gaithersburg, Maryland, USA. nayyar.iqbal@astrazeneca.com. 5. Global Medicines Development, AstraZeneca, Gaithersburg, Maryland, USA. 6. Global Medicines Development, AstraZeneca, Gothenburg, Sweden. 7. Global Clinical Research Metabolics, Bristol-Myers Squibb, Princeton, New Jersey, USA.
Abstract
AIMS: Greater reductions in glycated haemoglobin (HbA1c) with saxagliptin, a dipeptidyl peptidase-4 inhibitor, versus placebo add-on in patients with type 2 diabetes who had inadequate glycaemic control with dapagliflozin 10mg/d plus metformin were demonstrated after 24 weeks of treatment. Results over 52 weeks of treatment were assessed in this analysis. MATERIALS AND METHODS: Patients (mean baseline HbA1c 7.9%) receivingopen-label dapagliflozin 10mg/d plus metformin were randomized to double-blind saxagliptin 5 mg/d or placebo add-on. RESULTS: The adjusted mean change from baseline to week 52 in HbA1c was greater with saxagliptin than with placebo add-on -0.38% vs 0.05%; difference -0.42% (95% confidence interval -0.64, -0.20)]. More patients achieved the HbA1c target of <7% with saxagliptin than with placebo add-on (29% vs 13%), and fewer patients were rescued or discontinued the study for lack of glycaemic control with saxagliptin than with placebo add-on (19% vs 28%). Reductions from baseline in body weight (≤1.5 kg) occurred in both groups. Similar proportions of patients reported ≥1 adverse event with saxagliptin (58.2%) and placebo add-on (58.0%); no new safety signals were detected. Hypoglycaemia was infrequent in both treatment groups (≤2.5%), with no major episodes. The rate of urinary tract infections was similar in the saxagliptin and placebo add-on groups (7.8% vs 7.4%). The incidence of genital infections was 3.3% with saxagliptin versus 6.2% with placebo add-on. CONCLUSIONS: Triple therapy with saxagliptin add-on to dapagliflozin plus metformin for 52 weeks resulted in sustained improvements in glycaemic control without an increase in body weight or increased risk of hypoglycaemia.
RCT Entities:
AIMS: Greater reductions in glycated haemoglobin (HbA1c) with saxagliptin, a dipeptidyl peptidase-4 inhibitor, versus placebo add-on in patients with type 2 diabetes who had inadequate glycaemic control with dapagliflozin 10 mg/d plus metformin were demonstrated after 24 weeks of treatment. Results over 52 weeks of treatment were assessed in this analysis. MATERIALS AND METHODS:Patients (mean baseline HbA1c 7.9%) receiving open-label dapagliflozin 10 mg/d plus metformin were randomized to double-blind saxagliptin 5 mg/d or placebo add-on. RESULTS: The adjusted mean change from baseline to week 52 in HbA1c was greater with saxagliptin than with placebo add-on -0.38% vs 0.05%; difference -0.42% (95% confidence interval -0.64, -0.20)]. More patients achieved the HbA1c target of <7% with saxagliptin than with placebo add-on (29% vs 13%), and fewer patients were rescued or discontinued the study for lack of glycaemic control with saxagliptin than with placebo add-on (19% vs 28%). Reductions from baseline in body weight (≤1.5 kg) occurred in both groups. Similar proportions of patients reported ≥1 adverse event with saxagliptin (58.2%) and placebo add-on (58.0%); no new safety signals were detected. Hypoglycaemia was infrequent in both treatment groups (≤2.5%), with no major episodes. The rate of urinary tract infections was similar in the saxagliptin and placebo add-on groups (7.8% vs 7.4%). The incidence of genital infections was 3.3% with saxagliptin versus 6.2% with placebo add-on. CONCLUSIONS: Triple therapy with saxagliptin add-on to dapagliflozin plus metformin for 52 weeks resulted in sustained improvements in glycaemic control without an increase in body weight or increased risk of hypoglycaemia.
Authors: Juan P Frías; Jill Maaske; Lisa Suchower; Lars Johansson; Paul D Hockings; Nayyar Iqbal; John P H Wilding Journal: Diabetes Obes Metab Date: 2021-09-28 Impact factor: 6.408
Authors: Tina Vilsbøll; Ella Ekholm; Eva Johnsson; Ricardo Garcia-Sanchez; Nalina Dronamraju; Serge A Jabbour; Marcus Lind Journal: Diabetes Obes Metab Date: 2020-02-23 Impact factor: 6.577
Authors: Juan P Frias; Guillermo Gonzalez-Galvez; Eva Johnsson; Jill Maaske; Marcia A Testa; Donald C Simonson; Nalina Dronamraju; Ricardo Garcia-Sanchez; Anne L Peters Journal: Diabetes Obes Metab Date: 2020-03-09 Impact factor: 6.577